FindTrial
Sign In

A Cohort Study of Hemophagocytic Lymphohistiocytosis (HLH) in the First Affiliated Hospital of Nanchang University

A Cohort Study of Hemophagocytic Lymphohistiocytosis (HLH) in the First Affiliated Hospital of Nanchang University

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114975
Enrollment
Unknown
Registered
2025-12-19
Start date
2025-12-25
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophagocytic Lymphohistiocytosis

Interventions

Retrospective cohort:None
Prospective cohort:None

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Retrospective Cohort : Patients diagnosed with HLH at the First Affiliated Hospital of Nanchang University from September 10, 2013, until the initiation of this study. Prospective Cohort: 1.Patients diagnosed with HLH at the First Affiliated Hospital of Nanchang University from the initiation date of this study onward. 2.Availability of complete baseline characteristics and outcome measures (primary and secondary). 3.For secondary HLH(sHLH), complete laboratory and diagnostic indicators corresponding to the underlying etiology must be available.

Exclusion criteria

Exclusion criteria: Retrospective Cohort : Missing primary observation indicators. Prospective Cohort : 1.Patients with missing primary outcomes, secondary outcomes, or secondary indicators necessary for identifying the etiology. 2.Inability to comply with the cohort study requirements due to drug or alcohol addiction. 3.Patients are deemed by the investigators to have factors that may endanger their safety or affect their compliance. 4.Inability to obtain follow-up information for any reason (e.g., inability to access patient information, presence of severe comorbidities).

Design outcomes

Primary

MeasureTime frame
Baseline characteristics: Patient-related variables, including age, gender, race, ethnicity, ECOG score, SOFA score, DIC score, medical history, body temperature, blood pressure, heart rate, respiration, pulse, etiology, and treatments, etc.;Auxiliary examination indicators: complete blood count, liver and kidney function, triglycerides, serum ferritin, bone marrow cell morphology examination (to observe for the presence of 'hemophagocytosis'), fibrinogen, ultrasound/abdominal CT to determine the presence of hepatosplenomegaly;Etiology-related indicators;—

Secondary

MeasureTime frame
CNS-HLH Indicators;Indicators related to cellular immunotherapy or hematopoietic stem cell transplantation;Outcome Indicators;—

Countries

China

Contacts

Public ContactFei Li

The First Affiliated Hospital of Nanchang University

yx021021@sina.com+86 139 7003 8386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026